Cells: Human umbilical cord-derived mesenchymal stem cell (UC-MSC).
Days in culture: 5 days
• In year 2006, human MSCs are defined by the International Society for Cellular Therapy (ISCT) as below: –
Possess specific surface markers (CD105+, CD73+, CD90+, CD45-, CD34-, CD14-, CD11b-, CD79a-, CD19- and HLA-DR-).
Capable of differentiating into: –
Mesenchymal stem cells (MSC) are multipotent stem cells that could differentiate into multiple lineages including osteogenic (bone cells), adipogenic (fat cells), chondrogenic (cartilage) and neurogenic (nerve cells).
The most common sources of MSC in the body are bone marrow, umbilical cord, adipose tissues, dental pulp, and peripheral blood.
Potential MSC Therapies:
(6 years old kid；acute lymphoblastic leukemia (ALL); skin GvHD at Day14 following HSC transplantation）
*MSCs-FFM: MSC-Frankfurt am Main
（57 yrs old female；Type 2 diabetes mellitus；Diabetic foot ulcer）
–> After 1 month: No adverse effects
–> After 6 months:
√ 6-min walk test, short physical performance exam, and forced expiratory volume in 1 second test ↑
√ Female sexual quality of life questionnaire ↑
√ Inflammation marker (TNF-a) ↓
→ cGMP stem cell production laboratory
→ National Pharmaceutical Regulatory Agency (NPRA)
→ Medical Review & Ethics Committee (MREC)
→ Institutional Review Board